65 completed, 11 recruiting, 9 unknown, 6 terminated. 39 Phase 2, 24 Not applicable, 23 Phase 1, 4 Phase 3, 1 Early Phase 1.
Follow Non-alcoholic Steatohepatitis: new trials by email Literature Review of Non-alcoholic Steatohepatitis trials Research Report on Non-alcoholic Steatohepatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial ESG + lifestyle modification, Lifestyle modification - Obesity, Liver Diseases | Not applicable | Recruiting | Pichamol Jirapinyo, MD, MPH | 132 | 2025-06-24 | 2026-06-25 |
| Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants ACT500 tablets, Placebo - Non-alcoholic Steatohepatitis | Phase 1 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 72 | 2025-03-06 | 2026-02-17 |
| Identification of Liver Fibrosis Biomarkers Identification of liver fibrosis biomarkers - Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease | Recruiting | Roche Diagnostics GmbH | 575 | 2025-02-01 | 2026-05-27 | |
| Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis PET scan of 68Ga-FAPI - Non-alcoholic Steatohepatitis | Phase 2 | Not yet recruiting | Central Hospital, Nancy, France | 72 | 2024-09-01 | 2024-02-09 |
| Reducing Non-Alcoholic Steatohepatitis Empagliflozin 10 miligrams (mg) - Non-alcoholic Steatohepatitis, Liver Diseases | Not applicable | Enrolling by invitation | Military University Hospital, Prague | 30 | 2024-04-01 | 2024-07-25 |
| Ultrasound and Attenuation Imaging Ultrasound Attenuation imaging measurement - Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver | Completed | Hywel Dda Health Board | 97 | 2024-02-14 | 2024-08-22 | |
| Clinical Effects of New Approach on Patients With Non-alcoholic Steatohepatitis Rosuvastatin 20mg - Non-alcoholic Steatohepatitis | Early Phase 1 | Completed | Beni-Suef University | 175 | 2023-12-17 | 2025-02-06 |
| A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) Efinopegdutide - Non-alcoholic Steatohepatitis, Hepatic Impairment | Phase 1 | Completed | Merck Sharp & Dohme LLC | 22 | 2023-11-21 | 2025-10-22 |
| Assessment of Fatty Liver With Thermo-acoustic Device Thermo-acuostic image acquisition of liver, MRI-PDFF estimation of hepatic fat - NASH, NAFLD | Withdrawn | Medical College of Wisconsin | 2023-11-02 | 2026-07-10 | ||
| Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue GIP/GLP-1a - Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis | Phase 1 / Phase 2 | Unknown | Dr Adnan Agha | 30 | 2023-10-01 | 2024-01-12 |
| Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg - Non-alcoholic Steatohepatitis | Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 120 | 2023-09-14 | 2024-08-26 |
| Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH DA-1241, Sitagliptin, DA-1241 Placebo - NON-ALCOHOLIC STEATOHEPATITIS | Phase 2 | Completed | NeuroBo Pharmaceuticals Inc. | 109 | 2023-09-14 | 2024-11-14 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants AZD9550, Placebo - Non-alcoholic Steatohepatitis | Phase 1 | Completed | AstraZeneca | 48 | 2023-05-02 | 2023-12-11 |
| A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function TVB-2640 - 50 mg - Non-alcoholic Steatohepatitis, Hepatic Impairment | Phase 1 | Completed | Sagimet Biosciences Inc. | 48 | 2023-05-01 | 2023-12-26 |
| A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations NNC0194-0499, Semaglutide, NNC0194-0499/Semaglutide A (40/3.20 mg/mL) - Non-alcoholic Steatohepatitis | Phase 1 | Completed | Novo Nordisk A/S | 53 | 2023-03-02 | 2024-02-29 |
| Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH J2H-1702, Placebo - Non-alcoholic Steatohepatitis | Phase 2 | Completed | J2H Biotech | 87 | 2023-02-15 | 2026-07-30 |
| A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants Cotadutide, Cotadutide-placebo, Moxifloxacin - Non-alcoholic Steatohepatitis | Phase 1 | Terminated | AstraZeneca | 31 | 2023-01-03 | 2023-04-05 |
| Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females Amg dose administration group, Amg dose administration group- Placebo, Bmg dose administration group - Non-alcoholic Steatohepatitis | Phase 1 | Completed | J2H Biotech | 16 | 2023-01-02 | 2025-12-17 |
| CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome Liver biopsy - Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis | Recruiting | Institut National de la Santé Et de la Recherche Médicale, France | 710 | 2022-12-06 | 2026-04-16 | |
| Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH 2mg of ASC41, 4mg of ASC41 (2 tablets of 2 mg ASC41), Placebo - Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis | Phase 2 | Active not recruiting | Gannex Pharma Co., Ltd. | 183 | 2022-09-30 | 2025-01-08 |
Showing 20 of 101. Sign in to see all of them.
Non-alcoholic Fatty Liver Disease (101) · Liver Diseases (17) · Fatty Liver (16) · Diabetes Mellitus, Type 2 (10) · Liver Cirrhosis (10) · Fibrosis (9) · Obesity (6) · Diabetes Mellitus (3) · Digestive System Diseases (3) · Hepatitis (3) · Carcinoma, Hepatocellular (2) · Hepatitis B (2) · Hepatitis C (2) · Hepatitis, Autoimmune (2) · Inflammation (2)
Digestive System Diseases (98) · Fatty Liver (85) · Liver Diseases (84) · Pathological Conditions, Signs and Symptoms (24) · Nutritional and Metabolic Diseases (18) · Pathologic Processes (18) · Metabolic Diseases (13) · Endocrine System Diseases (11) · Glucose Metabolism Disorders (11) · Diabetes Mellitus (8) · Fibrosis (8) · Signs and Symptoms (8) · Body Weight (7) · Nutrition Disorders (7) · Overnutrition (7)
semaglutide (6) · Vitamin E (3) · volixibat (3) · 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (2) · Bariatric Surgery (2) · Exercise (2) · Pegbelfermin (2) · Pioglitazone (2) · 4-(6-acetyl-3-(3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy)-2-propylphenoxy)butyric acid (1) · Acetylcysteine (1) · Atorvastatin (1) · BID protein, human (1) · Berberine (1) · Blood Specimen Collection (1) · Carnitine (1)
Novo Nordisk A/S (6) · AstraZeneca (4) · J2H Biotech (3) · Mirum Pharmaceuticals, Inc. (3) · Bristol-Myers Squibb (2) · Enanta Pharmaceuticals, Inc (2) · Institut National de la Santé Et de la Recherche Médicale, France (2) · Mayo Clinic (2) · Medical College of Wisconsin (2) · Perspectum (2) · Pfizer (2) · Philips Clinical & Medical Affairs Global (2) · Sunshine Lake Pharma Co., Ltd. (2) · Arrowhead Pharmaceuticals (1) · Asian Institute of Gastroenterology, India (1)
United States (47) · United Kingdom (19) · France (14) · Germany (11) · Canada (10) · Spain (9) · Belgium (8) · Puerto Rico (8) · Australia (7) · South Korea (7) · China (6) · Denmark (6) · India (5) · Italy (5) · Netherlands (5)
Adnan Agha, FRCP (1) · Annelize Koch (1) · Anthony E. Samir, MD (1) · Asmaa Mohammed Hussein, Assis.Prof (1) · Barham Abu Dayyeh, M.D. (1) · Charlotte Lemech, Doctor (1)
PMID 22913681, PMID 23887590, PMID 25195547, PMID 28702877, PMID 29548345, PMID 30431378, PMID 30554783, PMID 31437454, PMID 31536511, PMID 31697972, PMID 31727409, PMID 31796953, PMID 31870950, PMID 31887369, PMID 32234329, PMID 32360804, PMID 32925554, PMID 33039693, PMID 33185364, PMID 33860116, PMID 34329774, PMID 34621052, PMID 34740705, PMID 36001750, PMID 36334688, PMID 36513186, PMID 36520162, PMID 36690550, PMID 36738088, PMID 36930864, PMID 37328931, PMID 37786277, PMID 38058795, PMID 38112484, PMID 39132187, PMID 39291967, PMID 39392766, PMID 39412509, PMID 39481576, PMID 39601324, PMID 39798707, PMID 39884573, PMID 39897611, PMID 40116750, PMID 40305708, PMID 40430469, PMID 40480879, PMID 40677693, PMID 40969863, PMID 40980163
2019 (3), 2016 (2), 2018 (2), 2017 (1), 5UL1TR002373-04 (1), R01DK088925 (1), R01GM041935 (1), R21AT002901 (1)